Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VRL010
MIFTS: 60

Viral Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Viral Hepatitis

About this section

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 56 3 15 74
Hepatitis, Viral, Animal 45 74
Animal Viral Hepatitis 12 17
Viral Hepatitis with Hepatic Coma 12
Human Viral Hepatitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases Gastrointestinal diseases Immune diseases Liver diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1884
MeSH 45 D006524
Sources

Summaries for Viral Hepatitis

About this section
Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and hepatitis a. An important gene associated with Viral Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Human cytomegalovirus infection. The drugs Peginterferon alfa-2b and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and kidney, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

CDC : 3 Widespread outbreaks of hepatitis A across the United States

Wikipedia : 77 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Sources

Related Diseases for Viral Hepatitis

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 33.0 ALB F2
2 hepatitis a 32.5 AFP ALB F2 GPT SEPSECS SERPINA1
3 epstein-barr virus hepatitis 32.2 ALB F2
4 hepatitis c 32.0 GGT1 GPT IFNA1 IFNA2 KRT18 TNF
5 hepatitis d 31.9 F2 GPT IFNA2
6 hepatitis e 31.1 ALB F2 GPT TNF
7 acute liver failure 30.9 ALB F2 GPT SLC17A5
8 infantile liver failure syndrome 1 30.9 ALB F2 GPT SLC17A5
9 hepatic coma 30.9 ALB F2 GPT
10 fatty liver disease 30.7 FAS GGT1 SLC17A5 TNF
11 hepatitis b 30.5 AFP ALB F2 FGL2 GGT1 GPT
12 typhoid fever 30.5 ALB F2 TNF
13 schistosomiasis 30.5 ALB F2 TNF
14 hepatitis 30.3 AFP F2 FASLG GGT1 GPT IFNA1
15 hepatocellular carcinoma 30.3 AFP ALB F2 FASLG GGT1 HFE
16 obstructive jaundice 30.2 ALB F2 GGT1 GPT SLC17A5 TNF
17 autoimmune hepatitis 30.2 F2 FAS GGT1 GPT SEPSECS
18 alcohol abuse 30.2 ABCB7 GGT1 GPT SLC17A5
19 aplastic anemia 30.2 ALB FAS FASLG HFE TNF
20 alcoholic liver cirrhosis 30.1 AFP ALB F2 SLC17A5
21 protein-energy malnutrition 30.0 ALB GPT TNF
22 opisthorchiasis 30.0 AFP GPT TNF
23 gastroenteritis 30.0 ALB IFNA1 TNF
24 hepatic encephalopathy 29.9 ALB F2 GPT SLC17A5 TNF
25 acquired immunodeficiency syndrome 29.9 ALB IFNA1 IFNA2 TNF
26 fatty liver disease, nonalcoholic 1 29.9 GPT KRT18 SLC17A5
27 portal hypertension 29.8 ALB F2 GPT TNF
28 alpha-1-antitrypsin deficiency 29.8 ALB HFE SERPINA1
29 meningitis 29.8 ALB TLR2 TNF
30 diabetes mellitus, noninsulin-dependent 29.8 ALB GGT1 GPT SLC17A5 TNF
31 graft-versus-host disease 29.8 FAS FASLG TNF
32 vasculitis 29.8 IFNA2 SERPINA1 TNF
33 severe acute respiratory syndrome 29.7 IFNA1 MX1 TNF
34 scrub typhus 29.7 GPT SLC17A5 TLR2 TNF
35 bilirubin metabolic disorder 29.7 ALB F2 G6PD GGT1 GPT SLC17A5
36 biliary atresia 29.7 ALB GPT MX1
37 cholecystitis 29.7 ALB F2 GPT KRT18
38 sickle cell anemia 29.6 F2 G6PD TNF
39 nonalcoholic steatohepatitis 29.3 F2 GPT HFE KRT18 SLC17A5 TNF
40 alcoholic hepatitis 29.2 ALB F2 GPT KRT18 SLC17A5 TNF
41 gastrointestinal system disease 29.2 AFP ALB F2 GGT1 IFNA1 SERPINA1
42 liver cirrhosis 29.0 AFP ALB F2 GGT1 GPT HFE
43 malaria 28.8 ALB FASLG G6PD TLR2 TNF
44 liver disease 28.3 ABCB7 AFP ALB F2 FAS GGT1
45 fulminant viral hepatitis 12.4
46 porphyria cutanea tarda 11.4
47 paraquat poisoning 10.5 GPT SLC17A5
48 australia antigen 10.5
49 lymphomatoid granulomatosis 10.5 IFNA1 IFNA2
50 antipyrine metabolism 10.5 ALB F2

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis
Sources

Symptoms & Phenotypes for Viral Hepatitis

About this section

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ABCB7 AFP ALB F2 FAS FASLG
2 digestive/alimentary MP:0005381 9.8 ALB F2 FAS FASLG HFE TLR2
3 liver/biliary system MP:0005370 9.61 ABCB7 AFP ALB FAS FASLG HFE
4 mortality/aging MP:0010768 9.47 ABCB7 AFP ALB F2 FAS FASLG
Sources

Drugs & Therapeutics for Viral Hepatitis

About this section

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 299)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 215647-85-1, 99210-65-8
2
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36791-04-5 37542
3
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
7
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
8
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 154598-52-4 64139
9
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147127-20-6 464205
10
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
11
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Pravastatin Approved Phase 4 81093-37-0 54687
17
Simeprevir Approved Phase 4 923604-59-5 66576988
18
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 65666-07-1
19
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
20
Simvastatin Approved Phase 4 79902-63-9 54454
21
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
22
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
23
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
24
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 143491-57-0 60877
25
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 14052 3279
26
Rifampicin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5381226 5458213
27
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
28
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
29
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
30
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
31
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
33
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
34
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
36
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
38
Adefovir Investigational Phase 4 106941-25-7
39
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40
Cobalamin Experimental Phase 4 13408-78-1 6857388
41 Interferon alpha-2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 402)
# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
4 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
5 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
6 Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
7 Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
8 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
9 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
10 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
11 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
12 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4 Pravastatin;Rosuvastatin
13 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
14 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
15 Efficacy of Silymarin for Acute Hepatitis Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
16 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
17 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
18 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
19 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
20 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
21 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Recruiting NCT03854630 Phase 4 Engerix-B
22 HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure Recruiting NCT03642704 Phase 4 Reinforced preventive ARV therapy
23 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
24 Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
25 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Active, not recruiting NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
26 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
27 DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Enrolling by invitation NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
28 Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B Not yet recruiting NCT03933384 Phase 4 Tenofovir alafenamide;Entecavir
29 Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients Terminated NCT00122668 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor
30 Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Terminated NCT00122655 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors
31 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
32 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
33 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
34 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Unknown status NCT02371408 Phase 2, Phase 3 ravidasvir hydrochloride;sofosbuvir;ribavirin
35 Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
36 A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B Unknown status NCT01172392 Phase 3 Pegylated interferon-alpha-2a;Nucleotidic or Nucleosidic Treatment
37 BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection Unknown status NCT01641016 Phase 2, Phase 3 efavirenz
38 Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
39 Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Completed NCT01595685 Phase 3 Telbivudine;Entecavir
40 Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
41 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Completed NCT01426243 Phase 3
42 Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed NCT00946595 Phase 2, Phase 3 efavirenz/emtricitabin/tenofovir;lopinavir/ritonavir
43 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
44 Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed NCT00640263 Phase 3 lopinavir/ritonavir (LPV/r);Lamivudine (3TC)
45 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed NCT00573001 Phase 3 Tenofovir/Emtricitabine (Truvada) and Nevirapine;Tenofovir/Emtricitabine/Efavirenz (Atripla);Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);Tenofovir/Emtricitabine (Truvada) and Zidovudine
46 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
47 Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Completed NCT00495326 Phase 2, Phase 3 Nevirapine based therapy;Efavirenz based therapy;Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
48 Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load Completed NCT00454337 Phase 3 FTC/TDF + EFV or LPV/R +T20;FTC/TDF + EFV or LPV/R
49 Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 Completed NCT00421551 Phase 3 Darunavir;ritonavir
50 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients Completed NCT00391638 Phase 2, Phase 3 TRUVADA (EMTRICITABINE + TENOFOVIR DF)

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Sources

Genetic Tests for Viral Hepatitis

About this section
Sources

Anatomical Context for Viral Hepatitis

About this section

MalaCards organs/tissues related to Viral Hepatitis:

42
Testes, Liver, Kidney, T Cells, Thyroid, Monocytes, Brain
Sources

Publications for Viral Hepatitis

About this section

Articles related to Viral Hepatitis:

(show top 50) (show all 3253)
# Title Authors Year
1
Acute liver failure and misdiagnosis: Do not forget viral hepatitis E. ( 30017940 )
2019
2
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis. ( 30622241 )
2019
3
Guillain-Barré syndrome after viral hepatitis A. ( 30971337 )
2019
4
HIV, syphilis, and viral hepatitis among Latin American indigenous peoples and Afro-descendants: a systematic review. ( 31093241 )
2019
5
Assessing testing rates for viral hepatitis B and C by general practitioners in Flanders, Belgium: a registry-based study. ( 31072855 )
2019
6
Intravoxel incoherent motion derived liver perfusion/diffusion readouts can be reliable biomarker for the detection of viral hepatitis B induced liver fibrosis. ( 31032185 )
2019
7
Laboratory Diagnosis and Monitoring of Viral Hepatitis. ( 31046974 )
2019
8
Consultation on establishing robust integrated national reporting systems for viral hepatitis. ( 31054234 )
2019
9
Specific aspects of clinical course in case of combination of chronic pancreatitis and concomitant viral hepatitis C. ( 31055539 )
2019
10
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C. ( 31061822 )
2019
11
TIPE2 as a potential therapeutic target in chronic viral hepatitis. ( 30995133 )
2019
12
"Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination. ( 30975593 )
2019
13
Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. ( 30959469 )
2019
14
Electronic health record year and country of birth testing and patient navigation to increase diagnosis of chronic viral hepatitis. ( 30920700 )
2019
15
Sero Conversion of Viral Hepatitis among End Stage Renal Disease Patients on Hemodialysis in Kashmir: Results of a Prospective Study. ( 30894917 )
2019
16
Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. ( 30898817 )
2019
17
High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis. ( 30906743 )
2019
18
Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B. ( 30867825 )
2019
19
What Comes First: Treatment of Viral Hepatitis or Liver Cancer? ( 30874985 )
2019
20
Inflammasomes and their roles in the pathogenesis of viral hepatitis and their related complications; an updated systematic review. ( 30831142 )
2019
21
The study of regional peculiarities of parenteral viral hepatitis incidence dynamics among children as an instrument of developing complex regional social programs on the prevention of its increase. ( 30796870 )
2019
22
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. ( 30800429 )
2019
23
Viral Hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. ( 30817047 )
2019
24
Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. ( 30764780 )
2019
25
Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network. ( 30738196 )
2019
26
The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan. ( 30706354 )
2019
27
A territory-wide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. ( 30668746 )
2019
28
Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. ( 30629790 )
2019
29
Towards curative therapy of chronic viral hepatitis. ( 30641605 )
2019
30
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. ( 30647010 )
2019
31
Elimination of viral hepatitis by 2030: ambitious, but achievable. ( 30647012 )
2019
32
Civil society's critical role in the elimination of viral hepatitis. ( 30647013 )
2019
33
Project ECHO: democratising knowledge for the elimination of viral hepatitis. ( 30647014 )
2019
34
Accelerating the elimination of viral hepatitis for Indigenous peoples. ( 30647015 )
2019
35
Viral Hepatitis and Hepatocellular Carcinoma. ( 30593765 )
2019
36
Letter: the association between chronic viral hepatitis and metabolic syndrome. ( 30589966 )
2019
37
Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. ( 30589967 )
2019
38
Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. ( 30477810 )
2019
39
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. ( 30394948 )
2019
40
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. ( 29847179 )
2019
41
Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. ( 30151932 )
2019
42
Prevalence of Viral Hepatitis in Foreign-Born Populations in the Baltimore-Washington Metropolitan Area, 2009-2015. ( 30259234 )
2019
43
Need for recognizing atypical manifestations of childhood sporadic acute viral hepatitis warranting differences in management. ( 30269249 )
2019
44
Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure. ( 31103144 )
2018
45
Comparison of Dynamic Changes Among Various Prognostic Scores in Viral Hepatitis-Related Acute Liver Failure. ( 29735790 )
2018
46
A study of association between regulatory polymorphism in the IL-10 gene promoter region and acute viral hepatitis, and acute liver failure. ( 30109600 )
2018
47
Complement System as a Target for Therapies to Control Liver Regeneration/Damage in Acute Liver Failure Induced by Viral Hepatitis. ( 30402508 )
2018
48
Viral Hepatitis and Acute Liver Failure: Still a Problem. ( 29605067 )
2018
49
Acute liver failure due to severe herpes simplex viral hepatitis in an elderly woman: A case of initial infection. ( 30575229 )
2018
50
Acute Exacerbation to Autoimmune Hepatitis Mimicking Acute Viral Hepatitis-A Case Series and Review of Literature. ( 29743801 )
2018
Sources

Variations for Viral Hepatitis

About this section
Sources

Expression for Viral Hepatitis

About this section
Search GEO for disease gene expression data for Viral Hepatitis.
Sources

Pathways for Viral Hepatitis

About this section

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 1 38
Show member pathways
 12.91 FAS FASLG IFNA1 IFNA2 TLR2 TNF
2
Human cytomegalovirus infection 38
Show member pathways
 12.8 FAS FASLG IFNA1 IFNA2 TLR2 TNF
3
PI3K-Akt signaling pathway 38
Show member pathways
 12.33 FAS FASLG IFNA1 IFNA2 MX1 TLR2
4
NF-kappaB Signaling 4
12.23 FAS FASLG IFNA1 TLR2 TNF
5
Selenium Micronutrient Network 1
Show member pathways
 12.17 ALB F2 GGT1 TNF
6
Apoptosis and survival Caspase cascade 23
Show member pathways
 12.11 FAS FASLG KRT18 TNF
7
Proteoglycans in cancer 38
12.11 FAS FASLG TLR2 TNF
8
Tuberculosis 38
12.03 IFNA1 IFNA2 TLR2 TNF
9
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.03 FAS FASLG IFNA1 IFNA2 TNF
10
Bacterial infections in CF airways 23
Show member pathways
 11.95 FAS FASLG TLR2 TNF
11
Photodynamic therapy-induced AP-1 survival signaling. 1
11.34 FAS FASLG TNF
12
Necroptosis 38
Show member pathways
 11.26 FAS FASLG IFNA1 IFNA2 TNF
13
FOXA2 and FOXA3 transcription factor networks 1
11.22 AFP ALB F2
14
Signal transduction_JNK pathway 23
11.19 FAS FASLG TNF
15
African trypanosomiasis 38
11 FAS FASLG TNF
16
Cori Cycle 1
10.76 G6PD GPT
Sources

GO Terms for Viral Hepatitis

About this section

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 AFP ALB F2 FAS FASLG FGL2
2 extracellular exosome GO:0070062 9.65 ALB F2 FAS FASLG FGL2 G6PD
3 endoplasmic reticulum lumen GO:0005788 9.62 AFP ALB F2 SERPINA1
4 membrane raft GO:0045121 9.56 FAS FASLG TLR2 TNF
5 extracellular space GO:0005615 9.36 AFP ALB F2 FASLG GGT1 GPT

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.85 F2 FASLG IFNA1 IFNA2 TNF
2 cytokine-mediated signaling pathway GO:0019221 9.84 FASLG IFNA1 IFNA2 TNF
3 immune response GO:0006955 9.81 FAS FASLG TLR2 TNF
4 cellular protein metabolic process GO:0044267 9.78 AFP ALB F2 SERPINA1
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.7 FAS FASLG TNF
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.67 FASLG KRT18 TNF
7 blood coagulation GO:0007596 9.67 F2 IFNA1 IFNA2 SERPINA1
8 type I interferon signaling pathway GO:0060337 9.61 IFNA1 IFNA2 MX1
9 apoptotic signaling pathway GO:0097190 9.58 FAS FASLG TNF
10 defense response GO:0006952 9.56 IFNA1 IFNA2 MX1 TNF
11 leukotriene metabolic process GO:0006691 9.55 GGT1 TLR2
12 humoral immune response GO:0006959 9.5 IFNA1 IFNA2 TNF
13 acute-phase response GO:0006953 9.33 F2 HFE SERPINA1
14 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG KRT18 TNF
15 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 FASLG IFNA1 IFNA2 TNF
2 identical protein binding GO:0042802 9.17 ALB FAS G6PD MX1 SERPINA1 TLR2
Sources

Sources for Viral Hepatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....